Journal
EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
Volume 45, Issue 5, Pages 286-291Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICL.0000000000000591
Keywords
Herpes zoster; Varicella zoster virus; Herpetic uveitis; Herpetic keratitis; Vaccination
Categories
Ask authors/readers for more resources
Varicella-zoster virus (VZV) is the etiologic agent of both chickenpox and Herpes zoster (HZ). In the United States, there are around one million cases of HZ per year. Ten percent of HZ cases are subtyped as herpes zoster ophthalmicus (HZO) specifically and involve the V1 distribution. Herpes zoster ophthalmicus is a significant cause of blindness in the United States. This article will provide a basic overview of VZV, HZ, and HZO with a focus on preventative measures in an effort to prevent blindness through improving clinician awareness and education. The differences in clinical effectiveness and duration of effectiveness of the live (Zostavax) and recombinant vaccines (Shingrix) are illustrated. There is now a trend toward using the recombinant vaccine as recommended by the Advisory Committee for Immunization Practices (ACIP) for healthy adults 50 or older.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available